FQ
TVRD

First Quadrant’s Tvardi Therapeutics TVRD Stock Holding History

First Quadrant’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-444
Closed -$247K – 552
2021
Q3 		$247K Sell
444
-1,534
-78% -$770K 0.03% 322
2021
Q2 		$1.02M Buy
+1,978
New +$1.25M 0.12% 163
2019
Q1 		– Sell
-456
Closed -$214K – 833
2018
Q4 		$214K Hold
456
– – 0.02% 525
2018
Q3 		$393K Buy
+456
New +$329K 0.01% 529

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

First Quadrant's TVRD Position: Q4 2021 in Review

First Quadrant sold out of Tvardi Therapeutics (TVRD) in Q4 2021, closing a stake of 444 shares — an estimated $247K sold.

First Quadrant first reported a position in TVRD in Q3 2018 and held it in 4 quarters. The position peaked at $1.02M in Q2 2021. 181 funds tracked by Wall St. Rank hold TVRD as of Q4 2021.

  • First Quadrant reported no remaining Tvardi Therapeutics position as of Q4 2021 after selling out during the quarter.
  • First Quadrant sold 444 Tvardi Therapeutics shares in Q4 2021, an estimated $247K.
  • First Quadrant first reported a position in Tvardi Therapeutics in Q3 2018 and held it in 4 quarters.
  • First Quadrant's Tvardi Therapeutics position peaked at $1.02M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2021.

Based on First Quadrant's 13F filing for Q4 2021, filed 27 Jan 2022.